I'm not sure that I am correctly understanding the one MS professional's interpretation of the answer. Was his reference to "putting only potentially successful patients in your trial" addressed specifically to the placebo arm of the trial? After all, it was the similarity of the placebo data that the questionnaire from the audience was asking about.
Harry, I agree with optimist, outliers could be on other side of the desired patient profile. The one time I interviewed to be part of a clinical trial I was turned down because my disease wasn't active enough. One would think I was the perfect patient as far as the drug company was concerned.
One other thing that Cherie got into in her thread over on mssucks is that 2 people died during the trials. Somehow I missed that news, to me that's a big deal even if the percentage of people who died is low. Still people died! I don't think that happened with the abcr drugs.
Users browsing this forum: No registered users